Review
Biochemistry & Molecular Biology
Weizhen Zeng, Xinyao Zhou, Sulan Yu, Ruihua Liu, Chrystie Wan Ning Quek, Haozhe Yu, Ryan Yong Kiat Tay, Xiang Lin, Yun Feng
Summary: This article discusses the treatment of Sjogren's syndrome, focusing on new drug targets and the latest clinical trials. The study found that current trials overlook the non-glandular symptoms that often accompany the disease, such as fatigue, depression, and anxiety. Emerging biological agents targeting dryness and these symptoms have been studied and proven effective and safe. Additionally, it is suggested to create better grading systems to assess disease activity and severity, and the future of treatment may lie in gene, stem-cell, and tissue-engineering therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Rheumatology
J. H. Koh, Y. Park, J. Lee, S-H Park, S-K Kwok
Summary: Persistent hypergammaglobulinaemia is associated with salivary gland and solid organ damage, while decreased IgG levels may attenuate the progression to solid organ dysfunction.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Multidisciplinary Sciences
Bhuwan Khatri, Kandice L. Tessneer, Astrid Rasmussen, Farhang Aghakhanian, Tove Ragna Reksten, Adam Adler, Ilias Alevizos, Juan-Manuel Anaya, Lara A. Aqrawi, Eva Baecklund, Johan G. Brun, Sara Magnusson Bucher, Maija-Leena Eloranta, Fiona Engelke, Helena Forsblad-d'Elia, Stuart B. Glenn, Daniel Hammenfors, Juliana Imgenberg-Kreuz, Janicke Liaaen Jensen, Svein Joar Auglaend Johnsen, Malin Jonsson, Marika Kvarnstrom, Jennifer A. Kelly, He Li, Thomas Mandl, Javier Martin, Gaetane Nocturne, Katrine Braekke Norheim, Oyvind Palm, Kathrine Skarstein, Anna M. Stolarczyk, Kimberly E. Taylor, Maria Teruel, Elke Theander, Swamy Venuturupalli, Daniel J. Wallace, Kiely M. Grundahl, Kimberly S. Hefner, Lida Radfar, David M. Lewis, Donald U. Stone, C. Erick Kaufman, Michael T. Brennan, Joel M. Guthridge, Judith A. James, R. Hal Scofield, Patrick M. Gaffney, Lindsey A. Criswell, Roland Jonsson, Per Eriksson, Simon J. Bowman, Roald Omdal, Lars Ronnblom, Blake Warner, Maureen Rischmueller, Torsten Witte, A. Darise Farris, Xavier Mariette, Marta E. Alarcon-Riquelme, Caroline H. Shiboski, Marie Wahren-Herlenius, Wan-Fai Ng, Kathy L. Sivils, Indra Adrianto, Gunnel Nordmark, Christopher J. Lessard
Summary: This study identifies ten novel genetic risk regions associated with Sjogren's disease, implicating genes involved in immune and salivary gland function.
NATURE COMMUNICATIONS
(2022)
Article
Rheumatology
Maxime Beydon, Raphaele Seror, Veronique Le Guern, Pascale Chretien, Xavier Mariette, Gaetane Nocturne
Summary: This study compared disease characteristics between primary Sjogren's syndrome (pSS) patients of African ancestry and Caucasian ancestry. The results showed that patients of African ancestry had younger age at diagnosis, higher titre of gammaglobulins, higher rates of positive anti-SSA and anti-RNP antibodies, and more frequent systemic complications. Factors associated with disease activity were sub-Saharan African ancestry, rheumatoid factor, and anti-RNP positivity. In conclusion, patients of African ancestry displayed higher disease activity with increased B-cell activation.
Review
Medicine, General & Internal
Claudio Vitali, Antonina Minniti, Francesca Pignataro, Wanda Maglione, Nicoletta Del Papa
Summary: Despite the new biotechnological agents offering new possibilities for treating pSS, completed therapeutic trials have not yielded satisfactory results. Issues such as the extreme variability of patient phenotypes and the indolent nature of the disease leading to irreversible features in some patients have been identified as reasons for the poor outcomes. Advances in disease biomarker research are also discussed as potential solutions to improve patient selection and early diagnosis.
FRONTIERS IN MEDICINE
(2021)
Article
Medicine, General & Internal
Maen D. Abou Ziki, Roy Taoutel, Julian C. Hong, David N. Podell
Summary: Sjogren's syndrome is an autoimmune disease that can cause severe multi-organ complications. Pleural effusions are a rare complication of this disease, and prognostic biomarkers help assess disease severity.
JOURNAL OF MEDICAL CASE REPORTS
(2022)
Review
Biochemistry & Molecular Biology
Joa Kim, Yun-Sung Kim, Sung-Hwan Park
Summary: Metformin, a first-line agent for type 2 diabetes, shows potential as a treatment strategy for Sjogren's syndrome by modulating AMPK and mTOR pathways to enhance immunoregulatory response and ameliorate salivary gland function.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Rheumatology
Valerie Devauchelle-Pensec, Alen Zabotti, Guillermo Carvajal-Alegria, Nenad Filipovic, Sandrine Jousse-Joulin, Salvatore De Vita
Summary: Salivary gland ultrasonography plays an important role in detecting structural abnormalities in primary Sjogren's Syndrome, and could potentially be used for classification. The ongoing HarmonicSS project, supported by the EU, aims to apply artificial intelligence to SGUS in pSS for future study. Many questions remain unresolved, but data collected so far suggest that SGUS will be a significant tool in the study of pSS in the near future.
Article
Immunology
Yung-Hsiang Chao, Chin-Hsiu Liu, Yu-An Pan, Fu-Shun Yen, Jeng-Yuan Chiou, James Cheng-Chung Wei
Summary: This population-based cohort study found that patients with a history of endometriosis have an increased risk of developing Sjogren's syndrome, especially within the first five years after diagnosis, and in the age group of 20-39.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Alojzija Hocevar, George A. Bruyn, Lene Terslev, Juan Jose De Agustin, Daryl MacCarter, Stavros Chrysidis, Paz Collado, Christian Dejaco, Viktoria Fana, Gerogios Filippou, Stephanie Finzel, Frederique Gandjbakhch, Petra Hanova, Daniel Hammenfors, Cristina Hernandez-Diaz, Annamaria Iagnocco, Mohamed Atia Mortada, Nevsun Inanc, Esperanza Naredo, Sarah Ohrndorf, Nejc Perko, Wolfgang A. Schmidt, Giorgio Tamborrini, Matija Tomsic, Isabelle Chary-Valckenaere, Alen Zabotti, Helen Keen, Carlos Pineda, Maria-Antonietta D'agostino, Sandrine Jousse-Joulin
Summary: The objective of this study was to develop and assess the reliability of a consensus-based semiquantitative colour Doppler ultrasound scoring system for pathologic salivary gland vascularization in patients with primary Sjogren's syndrome (pSS). The study found that the developed scoring system showed good inter-reader reliability and excellent intra-reader reliability in both static images and patients.
Article
Rheumatology
Manuel Ramos-Casals, Nihan Acar-Denizli, Arjan Vissink, Pilar Brito-Zeron, Xiaomei Li, Francesco Carubbi, Roberta Priori, Natasa Toplak, Chiara Baldini, Enrique Faugier-Fuentes, Aike A. Kruize, Thomas Mandl, Minako Tomiita, Saviana Gandolfo, Kunio Hashimoto, Gabriela Hernandez-Molina, Benedikt Hofauer, Samara Mendieta-Zeron, Astrid Rasmussen, Pulukool Sandhya, Damien Sene, Virginia Fernandes Moca Trevisani, David Isenberg, Erik Sundberg, Sandra G. Pasoto, Agata Sebastian, Yasunori Suzuki, Soledad Retamozo, Bei Xu, Roberto Giacomelli, Angelica Gattamelata, Masa Bizjak, Stefano Bombardieri, Richard-Eduardo Loor-Chavez, Anneline Hinrichs, Peter Olsson, Hendrika Bootsma, Scott M. Lieberman
Summary: Childhood-onset primary Sjogren's syndrome is characterized by sicca features, parotid enlargement, and systemic disease, with age at diagnosis influencing the phenotypic expression of the disease. Symptom presentation includes dry mouth, dry eyes, positive ANA, anti-Ro/La antibodies, and positive RF, among others.
Article
Rheumatology
Alexandra Kachaner, Elisabeth Berge, Frederic Desmoulins, Christine Le Pajolec, Antoine Rousseau, Marc Labetoulle, Gaetane Nocturne, Xavier Mariette, Raphaele Seror
Summary: This study describes primary Sjogren's disease patients who do not have or have a low level of dryness, and compares them with Sjogren's disease patients who have oral or ocular dryness features.
Review
Immunology
Qipeng Zhan, Jianan Zhang, Yubin Lin, Wenjing Chen, Xinzou Fan, Dunfang Zhang
Summary: Sjogren's syndrome (SS) is a chronic autoimmune disease with dryness of the mouth and eyes as the main manifestations and systemic complications. IFNs, Th17 cell-related cytokines, and B cell-related cytokines are crucial for the pathogenesis of SS. Experimental treatments strategies include targeting Treg/Th17, mesenchymal stem cell treatment, targeting BAFF, inhibiting JAK pathway, etc.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Rheumatology
Robert I. Fox, Carla M. Fox, Jacques Eric Gottenberg, Thomas Doerner
Summary: SS is characterized by severe fatigue, dryness, pain, glandular swelling, and various systemic manifestations. Clinical trials have failed due to lack of extraglandular symptoms in enrolled patients. Future therapies should focus on improving symptoms and exploring innovative treatment directions.
Article
Health Care Sciences & Services
Tzong-Hann Yang, Alison H. Chang, Yen-Fu Cheng, Chin-Shyan Chen, Herng-Ching Lin
Summary: This study investigated the association between Sjogren's syndrome and chronic otitis media using a representative dataset of the Taiwanese population. The findings showed that patients with chronic otitis media were more likely to have Sjogren's syndrome. This finding can guide physicians in counseling patients with Sjogren's syndrome on the possibility of chronic otitis media occurrence.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Rheumatology
Hiromu Ito, Keiichiro Nishida, Toshihisa Kojima, Isao Matsushita, Masayo Kojima, Shintaro Hirata, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masaaki Mori, Akio Morinobu, Atsuko Murashima, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Takeo Nakayama, Hisashi Yamanaka, Yutaka Kawahito, Masayoshi Harigai
Summary: This study aimed to update the clinical practice guidelines for the management of rheumatoid arthritis (RA) in Japan and develop an algorithm for non-drug and surgical treatments. The guidelines were updated using the Grading of Recommendations, Assessment, Development, and Evaluation method, and recommendations were developed based on 19 clinical questions regarding non-drug and surgical treatments. The study also created an original algorithm for the treatment of RA.
MODERN RHEUMATOLOGY
(2023)
Article
Rheumatology
Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Hiromu Ito, Toshihisa Kojima, Isao Matsushita, Keiichiro Nishida, Masaaki Mori, Atsuko Murashima, Hisashi Yamanaka, Takeo Nakayama, Masayo Kojima, Masayoshi Harigai
Summary: The Japan College of Rheumatology has updated the clinical practice guidelines for rheumatoid arthritis, providing a useful tool for rheumatologists, healthcare professionals, and patients to make shared decisions in various clinical situations.
MODERN RHEUMATOLOGY
(2023)
Article
Rheumatology
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B. McInnes, Naveed Sattar, Tanja A. Stamm, Tsutomu Takeuchi, Michael Trauner, Desiree van der Heijde, Marieke Voshaar, Kevin L. Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Ruediger R. Burmester, Johannes W. J. Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H. Choy, Catalin Codreanu, Bernard Combe, Mary K. Crow, Maarten de Wit, Paul Emery, Roy M. Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L. Hyrich, Annamaria Iagnocco, John D. Isaacs, Joel M. Kremer, Xavier Mariette, Peter Merkel, Eduardo F. Mysler, Peter Nash, Michael T. Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S. Smolen
Summary: This paper is an updated consensus document on the medical use of IL-6 pathway inhibition in the treatment of inflammatory diseases. The document provides comprehensive consensus statements based on systematic literature research and expert opinion, covering various aspects of IL-6 pathway inhibitors, including dosing, indications, and clinical considerations.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Yoshiya Tanaka, Masafumi Kawanishi, Megumi Nakanishi, Hironori Yamasaki, Tsutomu Takeuchi
Summary: Subcutaneous ozoralizumab treatment for 52 weeks demonstrated significant therapeutic effects and acceptable tolerability in patients with active rheumatoid arthritis.
MODERN RHEUMATOLOGY
(2023)
Review
Rheumatology
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe
Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Tsutomu Takeuchi, Sakae Tanaka, Mitsuru Murata, Yoshiya Tanaka
Summary: This study aimed to evaluate the efficacy and safety of TAS5315 in Japanese patients with refractory rheumatoid arthritis. The results showed numerical differences in disease activity improvement rates between the TAS5315 group and the placebo group at week 12, but the primary endpoint was not achieved. However, TAS5315 demonstrated advantages in disease activity and biomarker improvement, as well as higher risk of bleeding events within 36 weeks. Therefore, a risk-benefit analysis of TAS5315 should be considered.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Yoshiya Tanaka, Tsutomu Takeuchi, Derek Haaland, Stephen Hall, Nevsun Inanc, Zhanguo Li, Ricardo M. M. Xavier, Carlos Cara, Nicola Tilt, Peter C. C. Taylor
Summary: This study assessed the efficacy of Certolizumab pegol (CZP) in patients with early and established rheumatoid arthritis (RA) and found that it was effective in reducing symptoms in patients with different rheumatoid factors (RF) levels. CZP may be considered as a treatment option for RA.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Fang Song, Hisae Nakatani, Eiji Sugiyama, Shintaro Hirata
Summary: The objective of this study was to develop a nursing practice scale for evaluating the care provided to patients with rheumatoid arthritis receiving biological disease-modifying anti-rheumatic drugs. The results confirmed the reliability, criterion validity, and construct validity of the self-created 19-item nursing practice scale.
MODERN RHEUMATOLOGY
(2023)
Article
Rheumatology
Peter C. Taylor, Michael E. Weinblatt, Iain B. McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O'Shea, Didier Saurigny, Lorrie A. Schifano, Celia Shelton, Julia E. Smith, Millie Wang, Reena Wang, Sarah Watts, Roy M. Fleischmann
Summary: This study investigated the efficacy and safety of otilimab in patients with active rheumatoid arthritis. The results showed that otilimab did not achieve the primary endpoint of ACR20 and did not demonstrate non-inferiority to sarilumab in this patient population.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Satoshi Takanashi, Yasushi Kondo, Shuntaro Saito, Jun Kikuchi, Hironari Hanaoka, Tsutomu Takeuchi, Yuko Kaneko
Summary: Rituximab is an effective treatment option for patients with lymphoproliferative disorder and rheumatoid vasculitis, showing significant improvements in disease activity scores and reduction in prednisolone dosage, with a good safety profile.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Pharmacology & Pharmacy
Tsutomu Takeuchi, Yukihiro Chino, Yoko Mano, Masafumi Kawanishi, Yuri Sato, Saeko Uchida, Yoshiya Tanaka
Summary: A population pharmacokinetic (PK) model was developed to assess the effects of potential PK covariates on the PK of ozoralizumab. The model adequately described the PK of ozoralizumab in Japanese patients with rheumatoid arthritis, and body weight was found to have the greatest impact on its PK.
JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Rheumatology
Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi, Megumi Nakanishi, Hirotaka Watase, Yoko Mano, Yuri Sato, Saeko Uchida, Yoshiya Tanaka
Summary: This study aimed to analyze the pharmacokinetics (PK) of Ozoralizumab (OZR) and its correlation with clinical efficacy in rheumatoid arthritis (RA) patients. The results showed that the maximum plasma concentration (C-max) of OZR was reached in 6 days, with a half-life of 18 days. The exposure of OZR correlated negatively with patient body weight and was not significantly affected by other patient baseline characteristics. The efficacy of OZR was sustained independent of trough concentration when administered subcutaneously at a dose of 30 mg every 4 weeks for 52 weeks.
ARTHRITIS RESEARCH & THERAPY
(2023)
Article
Immunology
Hirofumi Watanabe, Sho Mokuda, Tadahiro Tokunaga, Hiroki Kohno, Michinori Ishitoku, Kei Araki, Tomohiro Sugimoto, Yusuke Yoshida, Toshihiro Yamamoto, Mayuko Matsumoto, Junya Masumoto, Shintaro Hirata, Eiji Sugiyama
Summary: This study found that FXIII-A is expressed in M2 macrophages, while FXIII-B is expressed in fibroblast-like synoviocytes. In patients with rheumatoid arthritis, anti-IL-6 receptor antibody treatment leads to decreased FXIII activity. IL-6 promotes the expression of FXIII-A, while the anti-IL-6 receptor antibody inhibits FXIII-A expression. FXIII-B is more abundantly secreted in synoviocytes and it elevates the expression of genes associated with antiapoptotic molecules and chemokines.
INFLAMMATION AND REGENERATION
(2023)
Article
Rheumatology
Tomohiro Sugimoto, Ai Yorishima, Naoya Oka, Sho Masuda, Naoki Nakamoto, Genki Kidoguchi, Hirofumi Watanabe, Yusuke Yoshida, Sho Mokuda, Shintaro Hirata
Summary: This study describes a case of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis developed after COVID-19 vaccination. The patient was also diagnosed with slowly progressive insulin-dependent diabetes positive for anti-glutamic acid decarboxylase antibody. The patient expressed the DRB1*04:05 allele in the human leukocyte antigen test.
MODERN RHEUMATOLOGY CASE REPORTS
(2023)
Article
Rheumatology
Yuki Murao, Yusuke Yoshida, Naoya Oka, Ai Yorishima, Sho Masuda, Tomohiro Sugimoto, Rina Ono, Yutaka Hirokawa, Shintaro Hirata
Summary: This case report presents the clinical manifestations and treatment course of a 74-year-old woman with occult middle ear involvement of ANCA-associated vasculitis (OMAAV), detected by FDG-PET/CT. The FDG-PET/CT showed remarkable uptake in the surrounding areas of the bilateral Eustachian tubes and left middle ear, which was only partially detected on magnetic resonance imaging. The patient's positive response to immunosuppressive therapy suggests that FDG-PET/CT can be helpful in distinguishing OMAAV from other non-inflammatory middle ear diseases and detecting occult treatment-responsive OMAAV lesions.
MODERN RHEUMATOLOGY CASE REPORTS
(2023)